Stryker SYK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $3.21B-29.7% | $4.56B+20.0% | $3.8B+0.8% | $3.77B+23.4% | $3.06B-21.3% | |
| Orthopaedics: | $2.81B+7.8% | $2.61B+15.7% | $2.25B+0.1% | $2.25B-19.9% | $2.81B+10.0% | |
| Net Sales by Product | ||||||
| Endoscopy | $868M-24.2% | $1.15B+27.8% | $896M-0.3% | $899M+3.7% | $867M-13.8% | |
| Hips | $460M-7.8% | $499M+9.2% | $457M-1.9% | $466M+5.2% | $443M-4.3% | |
| Instruments | $920M-0.5% | $925M+21.7% | $760M-1.0% | $768M-8.4% | $838M+6.1% | |
| Knees | $670M-10.5% | $749M+19.3% | $628M-1.9% | $640M+0.2% | $639M-7.0% | |
| Medical | $902M-29.8% | $1.28B+30.4% | $985M-0.5% | $990M+4.8% | $945M-17.3% | |
| Ortho Tech | $646M— | —— | —— | —— | $617M— | |
| Spine | $2M-75.0% | $8M+33.3% | $6M+20.0% | $5M-97.0% | $166M-10.8% | |
| Trauma and Extremities | $1.04B-4.7% | $1.09B+13.1% | $960M+0.3% | $957M+1.3% | $945M-5.1% | |
| Vascular | $517M-4.1% | $539M+2.7% | $525M+5.4% | $498M+22.7% | $406M+19.1% | |
| Net Sales by Geography | ||||||
| International | $1.54B-10.8% | $1.73B+16.4% | $1.49B+1.2% | $1.47B+2.9% | $1.43B-8.8% | |
| United States | $4.48B-17.7% | $5.44B+19.0% | $4.57B+0.4% | $4.55B+2.6% | $4.44B-8.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
